Braidwell L.P. 13F annual report
Braidwell L.P. is an investment fund managing more than $1.77 trillion ran by Manish Mital. There are currently 51 companies in Mr. Mital’s portfolio. The largest investments include Apogee Therapeutics Inc and Neurocrine Biosciences, together worth $223 billion.
$1.77 trillion Assets Under Management (AUM)
As of 8th May 2024, Braidwell L.P.’s top holding is 1,842,515 shares of Apogee Therapeutics Inc currently worth over $122 billion and making up 6.9% of the portfolio value.
In addition, the fund holds 730,209 shares of Neurocrine Biosciences worth $101 billion, whose value grew 25.1% in the past six months.
The third-largest holding is Argenx Se worth $86.5 billion and the next is Vaxcyte worth $82.8 billion, with 1,212,703 shares owned.
Currently, Braidwell L.P.'s portfolio is worth at least $1.77 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Braidwell L.P.
The Braidwell L.P. office and employees reside in Stamford, Connecticut. According to the last 13-F report filed with the SEC, Manish Mital serves as the Chief Compliance Officer and General Counsel at Braidwell L.P..
Recent trades
In the most recent 13F filing, Braidwell L.P. revealed that it had opened a new position in
Apogee Therapeutics Inc and bought 1,842,515 shares worth $122 billion.
The investment fund also strengthened its position in Argenx Se by buying
195,224 additional shares.
This makes their stake in Argenx Se total 219,824 shares worth $86.5 billion.
On the other hand, there are companies that Braidwell L.P. is getting rid of from its portfolio.
Braidwell L.P. closed its position in IVERIC bio Inc on 15th May 2024.
It sold the previously owned 3,714,672 shares for $90.4 billion.
Manish Mital also disclosed a decreased stake in Neurocrine Biosciences by approximately 0.1%.
This leaves the value of the investment at $101 billion and 730,209 shares.
One of the largest hedge funds
The two most similar investment funds to Braidwell L.P. are Quantbot Technologies L.P. and Rbf Capital. They manage $1.77 trillion and $1.78 trillion respectively.
Manish Mital investment strategy
Braidwell L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 69.2% of
the total portfolio value.
The fund focuses on investments in the United States as
58.8% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
10% of the total holdings value.
On the other hand, small-cap stocks make up only 2.0% of the portfolio.
The average market cap of the portfolio companies is close to $12.8 billion.
The complete list of Braidwell L.P. trades based on 13F SEC filings
These positions were updated on May 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Apogee Therapeutics Inc |
Opened
1,842,515
|
$122,435,122,000 | 6.90% |
| Neurocrine Biosciences, Inc. |
4.77%
730,209
|
$100,710,425,000 | 5.68% |
| IVERIC bio Inc |
Closed
3,714,672
|
$90,377,970,000 | |
| Argenx Se |
793.59%
219,824
|
$86,549,105,000 | 4.88% |
| Vaxcyte, Inc. |
8.13%
1,212,703
|
$82,839,742,000 | 4.67% |
| Legend Biotech Corp |
106.68%
1,243,795
|
$69,764,462,000 | 3.93% |
| Penumbra Inc |
176.42%
295,892
|
$66,037,177,000 | 3.72% |
| Maravai Lifesciences Hldgs I |
Opened
7,221,960
|
$62,614,393,000 | 3.53% |
| Biogen Inc |
Closed
220,742
|
$61,372,898,000 | |
| Viking Therapeutics Inc |
Opened
713,100
|
$58,474,200,000 | 3.30% |
| Xenon Pharmaceuticals Inc |
38.80%
1,308,011
|
$56,309,874,000 | 3.17% |
| iRhythm Technologies Inc |
6.40%
483,257
|
$56,057,812,000 | 3.16% |
| Align Technology, Inc. |
18.29%
169,252
|
$55,501,116,000 | 3.13% |
| Natera Inc |
Closed
982,241
|
$54,534,020,000 | |
| Guardant Health Inc |
Opened
2,476,804
|
$51,096,467,000 | 2.88% |
| Cg Oncology Inc |
Opened
1,130,235
|
$49,617,317,000 | 2.80% |
| Keros Therapeutics, Inc. |
Opened
737,379
|
$48,814,490,000 | 2.75% |
| TransMedics Group, Inc. |
524.15%
614,531
|
$45,438,422,000 | 2.56% |
| Avadel Pharmaceuticals plc |
Opened
2,668,549
|
$45,071,793,000 | 2.54% |
| Glaukos Corporation |
75.05%
450,676
|
$42,494,240,000 | 2.39% |
| Enanta Pharmaceuticals Inc |
Closed
1,038,310
|
$41,989,256,000 | |
| Paragon 28, Inc. |
206.32%
3,365,609
|
$41,565,271,000 | 2.34% |
| Intuitive Surgical Inc |
54.96%
100,500
|
$40,108,545,000 | 2.26% |
| AMGEN Inc. |
Closed
161,500
|
$39,042,625,000 | |
| Day One Biopharmaceuticals I |
31.21%
2,173,704
|
$35,909,590,000 | 2.02% |
| 4d Molecular Therapeutics In |
Opened
1,052,485
|
$33,532,172,000 | 1.89% |
| Crinetics Pharmaceuticals In |
Closed
2,019,714
|
$32,436,607,000 | |
| OrthoPediatrics corp |
10.90%
1,107,770
|
$32,302,573,000 | 1.82% |
| Krystal Biotech Inc |
49.12%
177,089
|
$31,509,446,000 | 1.78% |
| Relay Therapeutics, Inc. |
Opened
3,743,999
|
$31,075,192,000 | 1.75% |
| Ironwood Pharmaceuticals Inc |
Opened
3,489,843
|
$30,396,533,000 | 1.71% |
| Bellus Health Inc |
Closed
4,126,194
|
$29,708,597,000 | |
| Dice Therapeutics Inc |
Closed
984,800
|
$28,214,520,000 | |
| Kiniksa Pharmaceuticals Ltd |
Opened
1,392,716
|
$27,478,287,000 | 1.55% |
| Thermo Fisher Scientific Inc. |
Opened
47,149
|
$27,403,470,000 | 1.54% |
| Merus N.V |
Closed
1,473,084
|
$27,104,746,000 | |
| Hillevax Inc |
Closed
1,620,216
|
$26,782,170,000 | |
| Aclaris Therapeutics Inc |
Closed
3,269,094
|
$26,446,970,000 | |
| Repligen Corp. |
Opened
142,836
|
$26,270,397,000 | 1.48% |
| Nevro Corp |
8.79%
1,776,368
|
$25,650,754,000 | 1.45% |
| Terns Pharmaceuticals Inc |
Closed
1,997,055
|
$23,645,131,000 | |
| Inspire Med Sys Inc |
Opened
101,492
|
$21,799,467,000 | 1.23% |
| AnaptysBio Inc |
Closed
973,073
|
$21,174,068,000 | |
| Cullinan Oncology, LLC |
Opened
1,240,865
|
$21,144,340,000 | 1.19% |
| Immunocore Hldgs Plc |
Closed
426,110
|
$21,066,878,000 | |
| Tourmaline Bio Inc |
Opened
906,820
|
$20,766,178,000 | 1.17% |
| Lexeo Therapeutics Inc |
Opened
1,322,277
|
$20,733,303,000 | 1.17% |
| Spyre Therapeutics Inc |
Opened
515,000
|
$19,533,950,000 | 1.10% |
| Syndax Pharmaceuticals Inc |
Closed
920,049
|
$19,431,435,000 | |
| Biomarin Pharmaceutical Inc. |
Opened
218,896
|
$19,118,377,000 | 1.08% |
| Globus Med Inc |
Closed
335,200
|
$18,985,728,000 | |
| Structure Therapeutics Inc |
Opened
435,823
|
$18,679,374,000 | 1.05% |
| Steris Plc |
Closed
95,694
|
$18,304,348,000 | |
| Biocryst Pharmaceuticals Inc. |
73.75%
3,379,577
|
$17,168,251,000 | 0.97% |
| Mirati Therapeutics Inc |
Closed
452,000
|
$16,805,360,000 | |
| Dyne Therapeutics, Inc. |
Closed
1,377,872
|
$15,873,085,000 | |
| iTeos Therapeutics, Inc. |
Opened
1,162,374
|
$15,854,781,000 | 0.89% |
| Mineralys Therapeutics Inc |
108.46%
1,147,154
|
$14,809,758,000 | 0.83% |
| Alector, Inc. |
25.75%
2,380,704
|
$14,331,838,000 | 0.81% |
| Vir Biotechnology Inc |
Closed
604,036
|
$14,055,918,000 | |
| Mersana Therapeutics Inc |
Closed
3,355,805
|
$13,792,359,000 | |
| Arcutis Biotherapeutics Inc |
Opened
1,300,000
|
$12,883,000,000 | 0.73% |
| Pacific Biosciences Calif In |
Closed
1,097,300
|
$12,706,734,000 | |
| Elevation Oncology Inc |
Opened
2,377,647
|
$12,197,329,000 | 0.69% |
| BridgeBio Pharma Inc |
Opened
344,827
|
$10,662,051,000 | 0.60% |
| Compass Therapeutics Inc |
Closed
3,247,847
|
$10,620,460,000 | |
| Arcellx Inc |
Closed
333,800
|
$10,284,378,000 | |
| Iovance Biotherapeutics Inc |
Opened
660,022
|
$9,781,526,000 | 0.55% |
| Deciphera Pharmaceuticals In |
81.19%
609,643
|
$9,589,684,000 | 0.54% |
| Axonics Inc |
Closed
166,704
|
$9,095,370,000 | |
| Olema Pharmaceuticals, Inc. |
Opened
704,344
|
$7,973,174,000 | 0.45% |
| Pulmonx Corp |
35.31%
752,541
|
$6,976,055,000 | 0.39% |
| Nuvation Bio Inc |
Closed
4,122,900
|
$6,844,014,000 | |
| Dbv Technologies S A |
35.22%
7,843,285
|
$5,927,170,000 | 0.33% |
| ALX Oncology Holdings Inc. |
Closed
1,249,900
|
$5,649,548,000 | |
| Outset Med Inc |
36.83%
2,400,427
|
$5,328,948,000 | 0.30% |
| Adaptive Biotechnologies Cor |
109.34%
1,357,490
|
$4,357,543,000 | 0.25% |
| Silk Rd Med Inc |
Closed
63,331
|
$2,478,142,000 | |
| Immatics N.v |
Closed
322,287
|
$2,223,780,000 | |
| Esperion Therapeutics Inc Ne |
Closed
1,211,519
|
$1,926,315,000 | |
| Harrow Inc |
91.33%
125,967
|
$1,666,543,000 | 0.09% |
| Replimune Group Inc |
Closed
73,665
|
$1,300,924,000 | |
| Avalo Therapeutics Inc |
Closed
247,254
|
$432,695,000 | |
| No transactions found | |||
| Showing first 500 out of 83 holdings | |||
Hedge funds similar to Braidwell L.P.
- Cramer Rosenthal Mcglynn
- Mountain Pacific Investment Advisers Inc/id
- Cullinan Associates Inc
- Chesley Taft & Associates
- Alpha Cubed Investments
- Rbf Capital
- Quantbot Technologies L.P.
- Fairview Capital Investment Management
- Level Four Advisory Services
- Blb&b Advisors
- Corvex Management L.P.
- Hawk Ridge Capital Management L.P.
- Northeast Consultants Inc
- Rice Hall James & Associates